Romero-Reyes M, Salvemini D. Cancer and Orofacial Pain. Med Oral Patol Oral Cir Bucal. 2016 Nov 1;21 (6):e665-71. 

 

doi:10.4317/medoral.21515

http://dx.doi.org/doi:10.4317/medoral.21515

 

 

1. Benoliel R, Epstein J, Eliav E, Jurevic R, Elad S. Orofacial pain in cancer: part I-mechanisms. J Dent Res. 2007;86:491-505.
http://dx.doi.org/10.1177/154405910708600604

 

2. Clark GT, Ram S. Orofacial pain and neurosensory disorders and dysfunction in cancer patients. Dent Clin North Am. 2008;52:183-202.
http://dx.doi.org/10.1016/j.cden.2007.09.003

 

3. Romero-Reyes M, Teruel A, Ye Y. Cancer and Referred Facial Pain. Curr Pain Headache Rep. 2015;19:1-9.
http://dx.doi.org/10.1007/s11916-015-0512-1

 

4. Schmidt BL. The Neurobiology of Cancer Pain. J Oral Maxillofac Surg. 2015;73(12 Suppl):S132-5.
http://dx.doi.org/10.1016/j.joms.2015.04.045

 

5. Johnston M, Yu E, Kim J. Perineural invasion and spread in head and neck cancer. Expert Review of Anticancer Therapy. 2012;12:359-71.
http://dx.doi.org/10.1586/era.12.9

 

6. Bapat AA, Hostetter G, Von Hoff DD, Han H. Perineural invasion and associated pain in pancreatic cancer. Nat Rev Cancer. 2011;11:695-707.
http://dx.doi.org/10.1038/nrc3131

 

7. Binmadi NO, Basile JR. Perineural invasion in oral squamous cell carcinoma: A discussion of significance and review of the literature. Oral oncology. 2011;47:1005-10.
http://dx.doi.org/10.1016/j.oraloncology.2011.08.002

 

8. Frunza A, Slavescu D, Lascar I. Perineural invasion in head and neck cancers - a review. Journal of medicine and life. 2014;7:121-3.

 

9. Nemec SF, Herneth AM, Czerny C. Perineural tumor spread in malignant head and neck tumors. Topics in magnetic resonance imaging:TMRI. 2007;18:467-71.
http://dx.doi.org/10.1097/rmr.0b013e3181645a0d

 

10. Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nature reviews Neuroscience. 2006;7:797-809.
http://dx.doi.org/10.1038/nrn1914

 

11. Schmidt BL, Hamamoto DT, Simone DA, Wilcox GL. Mechanism of cancer pain. Molecular interventions. 2010;10:164-78.
http://dx.doi.org/10.1124/mi.10.3.7

 

12. Schmidt BL. What pain tells us about cancer. Pain. 2015;156:S32-S4.
http://dx.doi.org/10.1097/j.pain.0000000000000099

 

13. Ye Y, Ono K, BernabŽ DG, Viet CT, Pickering V, Dolan JC, et al. Adenosine triphosphate drives head and neck cancer pain through P2X2/3 heterotrimers. Acta Neuropathologica Communications. 2014;2:62.
http://dx.doi.org/10.1186/2051-5960-2-62

 

14. Ye Y, Dang D, Zhang J, Viet CT, Lam DK, Dolan J, et al. Nerve growth factor links oral cancer progression, pain, and cachexia. Molecular Cancer Therapeutics. 2011;10:1667-76.
http://dx.doi.org/10.1158/1535-7163.MCT-11-0123

 

15. Bagan J, Sarrion G, Jimenez Y. Oral cancer: Clinical features. Oral oncology. 2010;46:414-7.
http://dx.doi.org/10.1016/j.oraloncology.2010.03.009

 

16. Gorsky M, Epstein JB, Oakley C, Le ND, Hay J, Stevenson-Moore P. Carcinoma of the tongue: a case series analysis of clinical presentation, risk factors, staging, and outcome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;98:546-52.
http://dx.doi.org/10.1016/j.tripleo.2003.12.041

 

17. Cuffari L, Siqueira JTT, Nemr K, Rapaport A. Pain complaint as the first symptom of oral cancer: A descriptive study. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology. 2006;102:56-61.
http://dx.doi.org/10.1016/j.tripleo.2005.10.041

 

18. Viet CT, Ye Y, Dang D, Lam DK, Achdjian S, Zhang J, et al. Re-expression of the methylatedEDNRBgene in oral squamous cell carcinoma attenuates cancer-induced pain. Pain. 2011;152:2323-32.
http://dx.doi.org/10.1016/j.pain.2011.06.025

 

19. Pickering V, Gupta RJ, Quang P, Jordan RC, Schmidt BL. Effect of peripheral endothelin-1 concentration on carcinoma-induced pain in mice. European Journal of Pain. 2008;12:293-300.
http://dx.doi.org/10.1016/j.ejpain.2007.06.001

 

20. Schmidt BL, Pickering V, Liu S, Quang P, Dolan J, Connelly ST, et al. Peripheral endothelin A receptor antagonism attenuates carcinoma-induced pain. European Journal of Pain. 2007;11:406-14.
http://dx.doi.org/10.1016/j.ejpain.2006.05.007

 

21. Lam DK, Dang D, Zhang J, Dolan JC, Schmidt BL. Novel animal models of acute and chronic cancer pain: a pivotal role for PAR2. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2012;32:14178-83.
http://dx.doi.org/10.1523/JNEUROSCI.2399-12.2012

 

22. Lam DK, Schmidt BL. Orofacial pain onset predicts transition to head and neck cancer. Pain. 2011;152:1206-9.
http://dx.doi.org/10.1016/j.pain.2011.02.009

 

23. Talmi YP, Waller A, Bercovici M, Horowitz Z, Pfeffer MR, Adunski A, et al. Pain experienced by patients with terminal head and neck carcinoma. Cancer. 1997;80:1117-23.
http://dx.doi.org/10.1002/(SICI)1097-0142(19970915)80:6<1117::AID-CNCR15>3.0.CO;2-B

 

24. Boerman RH, Maassen EM, Joosten J, Kaanders HA, Marres HA, van Overbeeke J, et al. Trigeminal neuropathy secondary to perineural invasion of head and neck carcinomas. Neurology. 1999;53:213-6.
http://dx.doi.org/10.1212/WNL.53.1.213

 

25. Reiter S, Gavish A, Winocur E, Emodi-Perlman A, Eli I. Nasopharyngeal carcinoma mimicking a temporomandibular disorder: a case report. Journal of orofacial pain. 2006;20:74-81.

 

26. Mackie AM, Epstein JB, Wu JS, Stevenson-Moore P. Nasopharyngeal carcinoma: the role of the dentist in assessment, early diagnosis and care before and after cancer therapy. Oral Oncol. 2000;36:397-403.
http://dx.doi.org/10.1016/S1368-8375(00)00034-8

 

27. Gronseth G, Cruccu G, Alksne J, Argoff C, Brainin M, Burchiel K, et al. Practice Parameter: The diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology. 2008;71:1183-90.
http://dx.doi.org/10.1212/01.wnl.0000326598.83183.04

 

28. Moazzam AA, Habibian M. Patients appearing to dental professionals with orofacial pain arising from intracranial tumors: a literature review. Oral Surgery Oral Medicine Oral Pathology and Oral Radiology. 2012;114:749-55.
http://dx.doi.org/10.1016/j.oooo.2012.06.017

 

29. D'Silva NJ, Summerlin DJ, Cordell KG, Abdelsayed RA, Tomich CE, Hanks CT, et al. Metastatic tumors in the jaws: a retrospective study of 114 cases. J Am Dent Assoc. 2006;137:1667-72.
http://dx.doi.org/10.14219/jada.archive.2006.0112

 

30. Hirshberg A, Shnaiderman-Shapiro A, Kaplan I, Berger R. Metastatic tumours to the oral cavity - Pathogenesis and analysis of 673 cases. Oral oncology. 2008;44:743-52.
http://dx.doi.org/10.1016/j.oraloncology.2007.09.012

 

31. Murillo J, Bagan JV, Hens E, Diaz JM, Leopoldo M. Tumors Metastasizing to the Oral Cavity: A Study of 16 Cases. Journal of Oral and Maxillofacial Surgery. 2013;71:1545-51.
http://dx.doi.org/10.1016/j.joms.2013.03.017

 

32. Lawes KP, Danford M, Di Palma S. Delayed metastasis to the mandible of esophageal adenocarcinoma. Head Neck Pathol. 2013;7:416-20.
http://dx.doi.org/10.1007/s12105-013-0450-3

 

33. Seoane J, Van der Waal I, Van der Waal RIF, Cameselle-Teijeiro J, Ant—n I, Tardio A, et al. Metastatic tumours to the oral cavity: a survival study with a special focus on gingival metastases. Journal of clinical periodontology. 2009;36:488-92.
http://dx.doi.org/10.1111/j.1600-051X.2009.01407.x

 

34. Iriarte Soldevilla JI, Unda Urz‡iz M, Angulo Cuesta J, Zubiaur L’bano C, Arceo R, Flores Corral N. [Trigeminal neuralgia. First manifestation of adenocarcinoma of the prostate]. Arch Esp Urol. 1993;46:54-6.

 

35. Albayram S, Adaletli I, Selcuk H, Gulsen F, Islak C, Kocer N. Breast Cancer Metastasis Involving Pterygopalatine Fossa: A Cause of Trigeminal Neuralgia. Headache: The Journal of Head and Face Pain. 2004;44:927-8.
http://dx.doi.org/10.1111/j.1526-4610.2004.04178_1.x

 

36. Kruse ALD, Luebbers HT, Obwegeser JA, Edelmann L, Graetz KW. Temporomandibular disorders associated with metastases to the temporomandibular joint: a review of the literature and 3 additional cases. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology. 2010;110:e21-e8.
http://dx.doi.org/10.1016/j.tripleo.2010.02.031

 

37. Schoenen J, Broux R, Moonen G. Unilateral Facial Pain as the First Symptom of Lung Cancer: Are there Diagnostic Clues? Cephalalgia. 1992;12:178-9.
http://dx.doi.org/10.1046/j.1468-2982.1992.1203178.x

 

38. Pembroke CA, Byrne A, Lester JF, Button M. Persistent unilateral facial pain in lung cancer patients with mediastinal nodal involvement. Lung Cancer. 2013;82:173-5.
http://dx.doi.org/10.1016/j.lungcan.2013.06.024

 

39. Bindoff LA, Heseltine D. Unilateral facial pain in patients with lung cancer: a referred pain via the vagus? Lancet. 1988;1(8589):812-5.
http://dx.doi.org/10.1016/S0140-6736(88)91668-6

 

40. Sarlani E, Schwartz AH, Greenspan JD, Grace EG. Facial Pain as First Manifestation of Lung Cancer: A Case of Lung Cancer-Related Cluster Headache and a Review of the Literature. Journal of orofacial pain. 2003;17:262-7.

 

41. Capobianco DJ. Facial Pain as a Symptom of Nonmetastatic Lung Cancer. Headache: The Journal of Head and Face Pain. 1995;35:581-5.
http://dx.doi.org/10.1111/j.1526-4610.1995.hed3510581.x

 

42. Dach F, Oliveira FAA, dos Santos AC, Speciali JG. Trigeminal Neuralgia as the Sole Symptom of Pancreatic Cancer. Headache: The Journal of Head and Face Pain. 2013;53:165-7.
http://dx.doi.org/10.1111/j.1526-4610.2012.02246.x

 

43. Webber B, Webber M, Keinan D. Extranodal large B cell lymphoma of the anterior maxilla. Case report and review of literature. The New York state dental journal. 2015;81:34-8.

 

44. Parihar S, Garg RK, Narain P. Primary extra-nodal non-Hodgkin's lymphoma of gingiva: A diagnostic dilemma. Journal of oral and maxillofacial pathology: Jomfp. 2013;17:320.
http://dx.doi.org/10.4103/0973-029X.119773

 

45. Oranger A, Carbone C, Izzo M, Grano M. Cellular mechanisms of multiple myeloma bone disease. Clinical & developmental immunology. 2013;2013:289458.
http://dx.doi.org/10.1155/2013/289458

 

46. Troeltzsch M, Oduncu F, Mayr D, Ehrenfeld M, Pautke C, Otto S. Root resorption caused by jaw infiltration of multiple myeloma: report of a case and literature review. J Endod. 2014;40:1260-4.
http://dx.doi.org/10.1016/j.joen.2013.12.030

 

47. Assaf AT, JŸrgens TP, Benecke AW, Riecke B, Blessmann M, Zrnc TA, et al. Numb Chin Syndrome: A Rare and Often Overlooked Symptom. Journal of Oral & Facial Pain & Headache. 2014;28:80-90.
http://dx.doi.org/10.11607/jop.994

 

48. Romo CG, Jain P, Cortes JE. Numb chin syndrome by precursor B acute lymphoblastic leukemia. American journal of hematology. 2014;89:860-1.
http://dx.doi.org/10.1002/ajh.23766

 

49. Reddy CG, Mauermann ML, Solomon BM, Ringler MD, Jerath NU, Begna KH, et al. Neuroleukemiosis: an unusual cause of peripheral neuropathy. Leukemia & Lymphoma. 2012;53:2405-11.
http://dx.doi.org/10.3109/10428194.2012.691480

 

50. Pelosof LC, Gerber DE. Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment. Mayo Clinic Proceedings. 2010;85:838-54.
http://dx.doi.org/10.4065/mcp.2010.0099

 

51. Epstein JB, Elad S, Eliav E, Jurevic R, Benoliel R. Orofacial pain in cancer: part II--clinical perspectives and management. J Dent Res. 2007;86:506-18.
http://dx.doi.org/10.1177/154405910708600605

 

52. Demarquay G, Didelot A, Rogemond V, Ryvlin P, Gouttard M, Garassus P, et al. Facial pain as first manifestation of anti-Hu paraneoplastic syndrome. The journal of headache and pain. 2010;11:355-7.
http://dx.doi.org/10.1007/s10194-010-0212-5

 

53. Romero-Reyes M, Head C, Cacalano NA, Jewett A. Potent induction of TNF-alpha during interaction of immune effectors with oral tumors as a potential mechanism for the loss of NK cell viability and function. Apoptosis. 2007;12:2063-75.
http://dx.doi.org/10.1007/s10495-007-0112-6

 

54. Jewett A, Cacalano NA, Teruel A, Romero M, Rashedi M, Wang M, et al. Inhibition of nuclear factor kappa B (NFkappaB) activity in oral tumor cells prevents depletion of NK cells and increases their functional activation. Cancer immunology, immunotherapy: CII. 2006;55:1052-63.
http://dx.doi.org/10.1007/s00262-005-0093-7

 

55. Magee MS, Snook AE, Marszalowicz GP, Waldman SA. Immunotherapeutic strategies to target prognostic and predictive markers of cancer. Biomarkers in medicine. 2013;7:23-35.
http://dx.doi.org/10.2217/bmm.12.110

 

56. van den Beuken-van Everdingen M, de Rijke J, Kessels A, Schouten H, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Annals of Oncology. 2007;18:1437-49.
http://dx.doi.org/10.1093/annonc/mdm056

 

57. Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms? Neurosci Lett. 2015;596:90-107.
http://dx.doi.org/10.1016/j.neulet.2014.10.014

 

58. Binczak M, Navez M, Perrichon C, Blanchard D, Bollet M, Calmels P, et al. Management of somatic pain induced by head-and-neck cancer treatment: Definition and assessment. Guidelines of the French Oto-Rhino-Laryngology- Head and Neck Surgery Society (SFORL). European Annals of Otorhinolaryngology, Head and Neck Diseases. 2014;131:243-7.
http://dx.doi.org/10.1016/j.anorl.2014.07.003

 

59. Campos MI, Campos CN, Aarestrup FM, Aarestrup BJ. Oral mucositis in cancer treatment: Natural history, prevention and treatment. Molecular and clinical oncology. 2014;2:337-40.

 

60. Barkokebas A, Silva IH, de Andrade SC, Carvalho AA, Gueiros LA, Paiva SM, et al. Impact of oral mucositis on oral-health-related quality of life of patients diagnosed with cancer. J Oral Pathol Med. 2015;44:746-51.
http://dx.doi.org/10.1111/jop.12282

 

61. Jawad H, Hodson NA, Nixon PJ. A review of dental treatment of head and neck cancer patients, before, during and after radiotherapy: part 2. Br Dent J. 2015;218:69-74.
http://dx.doi.org/10.1038/sj.bdj.2015.29

 

62. Viet CT, Corby PM, Akinwande A, Schmidt BL. Review of Preclinical Studies on Treatment of Mucositis and Associated Pain. Journal of Dental Research. 2014;93:868-75.
http://dx.doi.org/10.1177/0022034514540174

 

63. Connolly I, Zaleon C, Montagnini M. Management of Severe Neuropathic Cancer Pain: An Illustrative Case and Review. American Journal of Hospice and Palliative Medicine. 2013;30:83-90.
http://dx.doi.org/10.1177/1049909112443586

 

64. Scott-Warren J, Bhaskar A. Cancer pain management-Part I: General principles. Continuing Education in Anaesthesia, Critical Care & Pain. 2014. p. 285-91.
http://dx.doi.org/10.1093/bjaceaccp/mkt070

 

65. Steiner F, Evans J, Marsh R, Rigby P, James S, Sutherland K, et al. Mouth opening and trismus in patients undergoing curative treatment for head and neck cancer. International journal of oral and maxillofacial surgery. 2015;44:292-6.
http://dx.doi.org/10.1016/j.ijom.2014.12.009

 

66. Jawad H, Hodson NA, Nixon PJ. A review of dental treatment of head and neck cancer patients, before, during and after radiotherapy: part 1. Br Dent J. 2015;218:65-8.
http://dx.doi.org/10.1038/sj.bdj.2015.28

 

67. Clark GT, Ram S. Orofacial Pain and Neurosensory Disorders and Dysfunction in Cancer Patients. Dental Clinics of North America. 2008;52:183-202.
http://dx.doi.org/10.1016/j.cden.2007.09.003

 

68. Sharp H, Morris JC, Van Waes C, Gius D, Cooley-Zgela T, Singh AK. High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. American journal of clinical oncology. 2008;31:557-60.
http://dx.doi.org/10.1097/COC.0b013e318172d5de

 

69. Cockerham MB, Weinberger BB, Lerchie SB. Oral Glutamine for the Prevention of Oral Mucositis Associated with High-Dose Paclitaxel and Melphalan for Autologous Bone Marrow Transplantation. Annals of Pharmacotherapy. 2000;34:300-3.
http://dx.doi.org/10.1345/aph.19168

 

70. Grau JJ, Caballero M, Verger E, Monz— M, Blanch Jl. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta oto-laryngologica. 2009;129:1294-9.
http://dx.doi.org/10.3109/00016480802590451

 

71. Doyle T, Chen Z, Muscoli C, Bryant L, Esposito E, Cuzzocrea S, et al. Targeting the Overproduction of Peroxynitrite for the Prevention and Reversal of Paclitaxel-Induced Neuropathic Pain. The Journal of Neuroscience. 2012;32:6149-60.
http://dx.doi.org/10.1523/JNEUROSCI.6343-11.2012

 

72. Little JW, Doyle T, Salvemini D. Reactive nitroxidative species and nociceptive processing: determining the roles for nitric oxide, superoxide, and peroxynitrite in pain. Amino acids. 2012;42:75-94.
http://dx.doi.org/10.1007/s00726-010-0633-0

 

73. Salvemini D, Little JW, Doyle T, Neumann WL. Roles of reactive oxygen and nitrogen species in pain. Free Radical Biology and Medicine. 2011;51:951-66.
http://dx.doi.org/10.1016/j.freeradbiomed.2011.01.026

 

74. Janes K, Esposito E, Doyle T, Cuzzocrea S, Tosh DK, Jacobson KA, et al. A(3) adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways. Pain. 2014;155:2560-7.
http://dx.doi.org/10.1016/j.pain.2014.09.016

 

75. Janes K, Symons-Liguori AM, Jacobson KA, Salvemini D. Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics. British Journal of Pharmacology. 2016;173:1253-67.
http://dx.doi.org/10.1111/bph.13446

 

76. Chen Z, Janes K, Chen C, Doyle T, Bryant L, Tosh DK, et al. Controlling murine and rat chronic pain through A3 adenosine receptor activation. The FASEB Journal. 2012;26:1855-65.
http://dx.doi.org/10.1096/fj.11-201541

 

77. Little JW, Ford A, Symons-Liguori AM, Chen Z, Janes K, Doyle T, et al. Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. Brain. 2015;138:28-35.
http://dx.doi.org/10.1093/brain/awu330

 

78. Janes K, Little JW, Li C, Bryant L, Chen C, Chen Z, et al. The Development and Maintenance of Paclitaxel-induced Neuropathic Pain Require Activation of the Sphingosine 1-Phosphate Receptor Subtype 1. Journal of Biological Chemistry. 2014;289:21082-97.
http://dx.doi.org/10.1074/jbc.M114.569574

 

79. Janes K, Wahlman C, Little JW, Doyle T, Tosh DK, Jacobson KA, et al. Spinal neuroimmune activation is independent of T-cell infiltration and attenuated by A3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy. Brain, behavior, and immunity. 2015;44:91-9.
http://dx.doi.org/10.1016/j.bbi.2014.08.010

 

80. Varani K, Vincenzi F, Targa M, Paradiso B, Parrilli A, Fini M, et al. The stimulation of A3 adenosine receptors reduces bone-residing breast cancer in a rat preclinical model. European Journal of Cancer. 2013;49:482-91.
http://dx.doi.org/10.1016/j.ejca.2012.06.005

 

81. Tosh DK, Padia J, Salvemini D, Jacobson KA. Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain. Purinergic Signal. 2015;11:371-87.
http://dx.doi.org/10.1007/s11302-015-9459-2

 

82. Fishman P, Bar-Yehuda S, Liang BT, Jacobson KA. Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today. 2012;17:359-66.
http://dx.doi.org/10.1016/j.drudis.2011.10.007